Literature DB >> 17070799

Azithromycin has a direct relaxant effect on precontracted airway smooth muscle.

Christos Daenas1, Apostolia A Hatziefthimiou, Konstantinos I Gourgoulianis, Paschalis Adam Molyvdas.   

Abstract

Macrolides have been proven to have beneficial bacteriostatic and anti-inflammatory properties, but very little is known about the potential value of their bronchodilatory effect. Therefore, in the present study we investigated the effect of azithromycin on contractile responses of isolated rabbit tracheal strips to carbachol or KCl. Azithromycin has a relaxant, concentration-dependent effect on tracheal strips precontracted with carbachol (300 nM), significant from the concentration of 1 muM. The mechanical removal of epithelium did not alter the effect of azithromycin. Azithromycin (100 microM) also relaxed tracheal strips precontracted with KCl (80 mM) even in the presence of atropine (100 microM). Moreover, azithromycin (100 microM) decreased contractions induced by 300 nM and 10 microM carbachol to 55.4% and 80.5% of initial contraction, respectively. The relaxant effect of azithromycin persisted in both calcium free solution and in the presence of the calcium channel antagonist, verapamil. The relaxant effect of azithromycin was not altered by the pre-treatment of preparations with the inhibitors of Ca(2+)-ATPase (cyclopiazonic acid), Na(+)-K(+) ATPase (ouabain), Rho-associated kinase [(R)-(+)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride] (Y-27632) or the non-specific cAMP and cGMP phosphodiesterases inhibitor 3-isobutyl-1-methyl-2,6(1H,3H)-purinedione (IBMX). These results suggest that azithromycin has a concentration-dependent, epithelium-independent, direct relaxant effect on precontracted tracheal strips that is not mediated via inhibition of Ca(2+) influx or Ca(2+) release from intracellular stores. Also, it is not due to alteration of the function of Na(+)-K(+) ATPase and does not depend on the formation of cAMP/cGMP or the Rho/Rho-activated kinase pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070799     DOI: 10.1016/j.ejphar.2006.09.041

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  Azithromycin use in patients with cystic fibrosis.

Authors:  N Principi; F Blasi; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-17       Impact factor: 3.267

2.  Effects of azithromycin on bronchial remodeling in the natural model of severe neutrophilic asthma in horses.

Authors:  Sophie Mainguy-Seers; Roxane Boivin; Sheila Pourali Dogaheh; Francis Beaudry; Pierre Hélie; Alvaro G Bonilla; James G Martin; Jean-Pierre Lavoie
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

3.  The cellular and molecular basis of bitter tastant-induced bronchodilation.

Authors:  Cheng-Hai Zhang; Lawrence M Lifshitz; Karl F Uy; Mitsuo Ikebe; Kevin E Fogarty; Ronghua ZhuGe
Journal:  PLoS Biol       Date:  2013-03-05       Impact factor: 8.029

4.  Pharmacological ablation of the airway smooth muscle layer-Mathematical predictions of functional improvement in asthma.

Authors:  Graham M Donovan; Kimberley C W Wang; Danial Shamsuddin; Tracy S Mann; Peter J Henry; Alexander N Larcombe; Peter B Noble
Journal:  Physiol Rep       Date:  2020-06

5.  Atopic characteristics of wheezing children and responses to prednisolone.

Authors:  Tuomas Jartti; Pasi Lehtinen; Timo Vanto; Tytti Vuorinen; Heikki Hiekkanen; Jaakko Hartiala; Mika J Mäkelä; Olli Ruuskanen
Journal:  Pediatr Pulmonol       Date:  2007-12

Review 6.  Azithromycin in viral infections.

Authors:  Madeleine E Oliver; Timothy S C Hinks
Journal:  Rev Med Virol       Date:  2020-09-23       Impact factor: 11.043

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.